Clinical Trial

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenocarcinoma (EGA). The investigators hypothesize that this drug combination will be better tolerated than current first-line chemotherapy combinations for this disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-12 -> 2027-12 2026-06-24
minor Completion pushed: 2027-12 -> 2028-05 2026-06-24
Trial Details
NCT Number NCT04150640
Lead Sponsor University of Wisconsin, Madison
Collaborators: Ipsen
Conditions Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Enrollment 52 participants
Start Date 2020-07-13
Primary Completion 2027-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-23